Martin Alexander Gershon

White House CancerX Moonshot Accelerator

2024 - Current

Announced by the White House Cancer Moonshot in February, CancerX is a public-private partnership to boost innovation in the fight against cancer. Co-hosted by the Moffitt Cancer Center and Digital Medicine Society (DiMe), alongside the Office for the National Coordinator for Health Information Technology (ONC) and Office of the Assistant Secretary for Health (OASH), it convenes the many diverse stakeholders needed to unleash the power of innovation to reduce the burden of cancer for everyone.

Masterclass, AI Drug Discovery and Development in partneship with HLTH Community

2024

As the integration of AI into drug discovery, drug development, clinical trials, and broadly across healthcare systems accelerates, industry leaders are faced with challenging decisions on how best to advance technology that has the potential to be game changing and accretive. This masterclass will explore partnerships relating to AI in drug discovery, including the importance of innovation, strategy, and important business facing steps to commercialization. The drug discovery process is a systematic approach that involves identifying and designing new drug candidates, followed by testing to ensure their safety and efficacy before they are brought to market. It generally comprises four main stages: early drug discovery, pre-clinical phase, clinical phases, and regulatory approval. Join this meeting to discuss numerous topics on navigating this market, including the impact AI has on: Accelerated Lead Identification: can AI drastically reduce the time required for lead identification in drug discovery, which is crucial for rare diseases? Optimized Drug Design: can AI enhance drug design by intelligently tweaking molecular structures, reducing side effects, and improving efficacy? Predictive Analysis in Clinical Trials: can AI streamline clinical trials concerning patient recruitment and personalized responses, making trials more efficient and reducing the overall time and cost to bring new drugs to market? Decentralization of Clinical Trials: can decentralization combined with AI has the make clinical trials more adaptive, patient-centric, and cost-effective. The Business Models on the Road to Commercialization: what is important in the process of integration of these technologies into enterprises including large academic medical centers and biopharma? How does disruptive technology seamlessly integrate into the operations of these organizations? What do you need to know to be effective in using AI to drive drug discovery and development in your organization?

Masterclass, Capital Raising for Emerging Companies, AI Healthcare Investor Summit

2024

Healthcare AI and Technology Investor Summit (Live/Virtual) 1200+ Registered Registration Link https://lu.ma/f1mt0ziq Keynote Speaker: Peter Durlach, Microsoft Chief Strategy Officer, Healthcare and Life Sciences Summit Chairman: Dr. Martin Alexander Gershon, Managing Partner, Endeavor Venture Funds Martinalexander@gershoncapital.com $100B has been invested into healthcare AI by Google, Amazon, Microsoft, Nvidia, and Apple. $2.8B has already been invested in AI Healthcare companies in Q1 2024. But while technology giants support healthcare AI startups with billions of dollars in investment, healthcare providers and emerging companies alike are finding it difficult to navigate the complexities of AI deployment in this critical sector. Who’s Attending C-suite industry leaders from leading New York and Boston hospitals including Mass General Hospital, Dana Farber, Beth Israel Deaconess, Mayo Clinic, SUNY Downstate, Mount Sinai, Cleveland Clinic, Cedars-Sinai, and leading healthcare and Big Tech companies Merck, Pfizer, AstraZeneca, Bayer, Nestle, Boston Scientific, Medtronic, Amazon, Amgen, JNJ, Novartis, IQVIA, Samsung, Microsoft. Register for the Breakout Sessions as Space is Limited! Summit@gershoncapital.com Breakout Sessions: Masterclass 2 Financing Strategies for Emerging Healthcare and Life Sciences Companies in the Current Economic Environment Summit Chairman: Dr. Martin Alexander Gershon, Managing Partner, Endeavor Venture Funds Randall Stanicky, CFO, Click Therapeutics The industry that has raised the most amount of funding in 2024 is healthcare AI and biotech. Companies in that sector raised $15.7 billion, or 24% of all global funding, in Q1. But despite the positive signals from healthcare AI and biotech recent public market activity, many investors are still risk off as they continue to adjust to portfolio liquidity shortfalls from 2022. As investors focus on liquidity, founders will continue to face a challenging funding environment.

Masterclass, Burnout in the Workplace

2024

Healthcare AI and Technology Investor Summit Free Virtual Ticket 🔗 Register Here: https://lu.ma/f1mt0ziq Join me alongside leaders from HSBC, Mass General Brigham Hospital and esteemed guests from Microsoft Healthcare, Mayo Clinic, Novartis, and Sanofi as we tackle the critical issue of workplace burnout across industries. Keynote Speaker: Peter Durlach, Microsoft Chief Strategy Officer, Healthcare and Life Sciences We'll explore individual, community, and systemic interventions crucial for combating this pandemic-level challenge. Claim your FREE Virtual ticket with code MASTERCLASS BURNOUT and join us for insightful discussions on resilience, innovation, and sustainable solutions. 🔗 Register Here: https://lu.ma/f1mt0ziq And event Streaming Link https://event.on24.com/wcc/r/4643521/F2AC84AAC602E95B34C297144CB00EDA

AI Healthcare Summit Chairman

2024

Endeavor Venture Funds is Proud to bring you This Year’s Most Important Healthcare AI Event! HEALTHCARE AI AND TECHNOLOGY INVESTOR DEAL MAKING SUMMIT JULY 17th Live / Boston and Virtual https://lu.ma/f1mt0ziq Keynote Speaker: Peter Durlach, Microsoft Chief Strategy Officer, Healthcare and Life Sciences Closing Remarks: Jim Rogers, Board of Directors Mayo Collaborative Services, Chief Business Development Officer and Senior Administrator Generative AI, Mayo Clinic Summit Chairman: Dr. Martin Alexander Gershon, Managing Partner, Endeavor Venture Funds White House CancerX Moonshot Advisor https://www.linkedin.com/in/martingershon Endeavor@gershoncapital.com Date: July 17, 2024 4pm - 9 pm LIVE AND VIRTUAL Who’s attending *100 C-Suite industry leaders including CEO, CTO, CIO, CTO, CMO from Leading New York and Harvard Boston Hospitals including Mass General Hospital, Dana Farber, NY Health and Hospital, SUNY Downstate, Cleveland Clinic, Cedars-Sinai, GE Healthcare, Pharma, Medtech, Biotech and Big Tech companies including Merck, Pfizer, Astellas, Boston Scientific, Amazon, Amgen, Samsung and Microsoft *Remarkable unicorns like Click Therapeutics, Verily, Komodo, and Insilico Medicine. *25 Emerging companies in AI and healthtech from Microsoft Pegasus and Foundation Hub portfolio companies like Artisight, Pangaea Data, Outbound, RealizedCare, Signal1, and Marble, Endeavor companies like Vocxi Health, Code Blue, Pepper Bio and outstanding startups from Merck Digital Sciences Studio, PlugandPlay Accelerator, Techstars and more! *100 World Class Corporate and International Venture Investors from the U.S. and Europe! *Media Coverage Wall Street Journal Expect dynamic panel discussions on cutting edge topics in healthcare technology, one-on-one meetings between founders from remarkable companies and more than 100 VC investors, strategic leaders, coming together to drive new pilot projects and clinical studies.

Dr. Michael Boutin, Contributing Editor, Partnering for BetterHealth Newsletter

2024

Chief Medical Information Officer, New York Health and Hospitals

Moderator: AI and Technology Summit, The Roadmap to Integrating AI into Hospitals & Biopharma

2024

AI and Technology Investor Summit 2024, Endeavor and Foley & Lardner

Moderator: Playing the Long Game - The Roadmap to Integrate AI into the Healthcare System,

2024

Bentley University AI Summit 2024

Moderator, AI and Technology Healthcare Investor Summit

2024

AI and TECHNOLOGY HEALTHCARE INVESTOR SUMMIT Boston July 17th live and virtual ! Endeavor Venture Funds and Foley & Lardner Please join us by clicking the link below https://lu.ma/f1mt0ziq Over 600 registered attendees from Microsoft Merck Mass General Hospital Harvard in Healthcare Alumni Association Harvard Innovation Labs Sanofi Novartis Eli Lilly JNJ Amgen Mayo Clinic Massachusetts Hospital Association Massachusetts Life Sciences Center SUNY Downstate Medical Center NY Health and Hospitals Memorial Sloan Kettering including over 100+ investors from corporate and institutional VC and 25+ groundbreaking digital health companies from Microsoft Merck Techstars PlugNPlay

Dr David Berger, Contributing Editor, Partnering for BetterHealth Newsletter

2024

CEO, SUNY Downstate Medical Center

Felix Lee, Contributing Editor, Partnering for BetterHealth Newsletter

2024

US Head of Digital Health, Sanofi

Randall Stanicky, Contributing Editor, Partnering for BetterHealth Newsletter

2024

CFO, Click Therapeutics

Summit Co-host Healthcare Investing London 2024

2024

Forum Sponsor: AI Healthcare Growth Partnering and Deal Making

2024

Endeavor Venture Fund & Venture Studio extends a warm invitation to you to join our dynamic event on March 7, both live and virtually from NYC. Get ready for an exciting exchange of ideas, insights, and deal-making opportunities that will revolutionize the future of healthcare. SOLD OUT! Virtual tickets available Keynote Speaker: Sally Ann Frank, Worldwide Lead Health and Life Sciences, Microsoft for Startups Sponsor: Endeavor Venture Fund & Venture Studio   https://lnkd.in/esR_5rnu Coupon: HealthEcoHub10 For more information email FORUM@gershoncapital.com Host Venue:Foley & Lardner LLP The NYC Health Care Innovation Ecosystem: A Growth Partnering and Deal-Making Hub. Join us for an evening dedicated to fostering collaboration, connecting stakeholders, and driving investments in healthcare technology and solutions. Panelists: Dr Martin Alexander Gershon, Managing Partner and CIO, Endeavor Venture Fund & Venture Studio Matthew McMahon, Director, NIH SEED Felix Lee, US Digital Healthcare Medical Head, Sanofi Michael Bouton, Chief Medical Information Officer, NYC Health and Hospitals Ping Yeh, CEO, Vocxi Special Guests: Dr David Rhew, Global Chief Medical Officer, Microsoft Phillip Ebner, Exec Director Life Sciences, JP Morgan Jennifer Webster, Head Evidence Generation Platforms and Partnerships, Pfizer Julie Fishman, Global Commercial Head Digital Health, Astellas Kyle Kaniecki, VP Life Sciences and Healthcare, NYCEDC James Gibaldi, AVP Life Sciences and Healthcare, NYCEDC Dr David H Berger, CEO, SUNY Downstate Medical Center Ernesto C. Martinez-Villalpando, Head Corporate Development & Innovation, MassChallenge Colleen Healy, Senior Sales Director US Health and Life Sciences U.S., Microsoft George Santo, CFA, Executive Director Head of Northeast Life Sciences, JP Morgan Lily W., Sr. Manager, CVS Health Ventures Trey Bowles, Managing Director, Techstars

Editor-in-Chief, Partnering for BetterHealth

2024

Senior Editor, Partnering for BetterHealth Newsletter

2024

Senior Strategic Advisor, Pepper Bio

2023

Thrilled to be part of this amazing team as the new Senior Strategic Advisor at Pepper Bio BOSTON — Pepper Bio, the world's first transomics drug discovery company, announced the addition of Dr. Martin Alexander Gershon to its team as a Senior Advisor. Dr. Gershon, the managing partner and CIO of Endeavor Life Sciences Venture Funds and Senior Investor-in-Residence for Techstars NY powered by JPMorgan, who will support Pepper Bio’s strategic growth and partnership initiatives In addition, as Chairperson and moderator for several AI and Drug Discovery Conferences in 2023, Dr. Gershon is in a unique position to see the decision-making perspectives of institutional and corporate investors and industry leaders from Fortune 500 companies. Dr. Gershon states, “It was evident that Investors and Industry Leaders want two things from Founders: 1. Commercial validation that comes from the establishment of strategic partnerships and projects that verify commercial viability and product-market fit; and 2. Strong teams that can execute and deliver results and compelling data that defines the use cases and value of the technology. And Jon and Samantha can deliver on both of these points." “Dr. Gershon’s expertise will be immensely valuable to Pepper Bio as we start our next phase of growth,” said Jon Hu, the CEO and co-founder of Pepper Bio. “His track record attests to the impact that he’s had on other early-stage companies, especially investments for AI in drug discovery and rare diseases. His passions and experience align with our mission to end untreatable diseases, and together, I believe we can achieve that.” By harnessing the combined powers of AI, computational biology, and mathematical analysis, Pepper Bio provides the critical insights that help researchers determine if a drug or target will succeed before the costly clinical trial stage.

Interview, Featured Speaker on AI, HSBC Health 2035 Summit

2024

https://lnkd.in/gJ7QGfdc

Moderator, AI4 Conference, AI Diagnostics

2024

Featured Speaker, AI Summit London

2024

Senior Strategic and Financial Advisor, Code Blue

2024

Welcome to Code Blue! We detect strokes early, ensuring rapid response and early treatment using just your phone. Having won the Big Ideas Grand Prize at University of California, Berkeley (https://lnkd.in/dqrEMNZH), we are now collaborating with University of California, San Francisco, Endeavor Venture Fund & Venture Studio, and Microsoft to bring our technology public. We are thrilled to have Dr. D. Martin Alexander Gershon, MD, JD, MPH as our Senior Strategic and Financial Advisor. Dr. Martin Alexander Gershon, is the Managing Partner and CIO of Endeavor Life Sciences Venture Funds, Senior Executive Investor-in-Residence for Healthcare at J.P. Morgan Techstars, and Advisor to the White House Moonshot CancerX Accelerator Program. Dr. Gershon has served as Senior Strategic Advisor for Fortune 500 Companies including McKinsey, Goldman Sachs, Bain Capital, BlackRock, American Express, Tiger Global, GlaxoSmithKline, Bristol-Myers Squibb, Pfizer, Novartis, the Federal Reserve Board of Governors, the Bill and Melinda Gates Foundation, and the Rockefeller Foundation. Over the past 23 years he has led Endeavor Venture Funds to over 100 investments and built a thriving ecosystem of partnerships in Biopharma, Biotech, Healthtech, Medtech, Hospitals, Academic Medical Centers, and Venture Capital, that has established a deep network of C-Suite thought leaders who help guide Endeavor and and emerging startups to prepare now for the future ahead. We believe that Dr. Gershon will play a pivotal role in our strategic and financial growth over the next several years.

Advisor NYEDC Venture Capital Convening

2024

Featured Speaker, AI Global Conference, The Roadmap to Healthcare AI Commercialization

2024

At the 2024 1ArtificialIntelligence Conference, Dr. D. Martin Alexander Gershon, MD, JD, MPH, Managing Partner and CIO of Endeavor Venture Fund & Venture Studio, discussed the dynamic landscape of healthcare commercialization. He highlighted major investments by Apple, Google, Microsoft, and Amazon, driven by increased liquidity, regulatory support, and changing demographics. Apple: Leading in wearable sensors. Google: Advancing drug discovery. Microsoft: Innovating electronic healthcare records. Amazon: Expanding telemedicine. Gershon emphasized the importance of collaboration and supportive regulations. The potential to revolutionize healthcare, with advancements in patient monitoring, drug discovery, and telemedicine, promises a transformative future at the intersection of technology and medicine. Watch the video to learn more! https://lnkd.in/eKkfqhXY

Masterclass, The Future of AI in Healthcare, NYU Entrepreneurial Institute

2024

Chairperson and Moderator AI and Healthcare Track, LSX World Congress

2024

Keynote Speaker AI and Digital Healthcare

2024